Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.54 |
| ▸ | CCR2 | P41597 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | IKBKB | O14920 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418828 | 0.95 | ROCK2 (0.58) | ROCK2ROCK1CCR2CYP4A11CYP4F2 | |
| SCHEMBL5407821 | 0.91 | CYP4A11 (0.59) | ROCK2ROCK1CCR2CYP4A11CYP4F2 | |
| SCHEMBL5412560 | 0.83 | ROCK2 (0.62) | ROCK2ROCK1CCR2CYP4A11CYP4F2 | |
| SCHEMBL5419426 | 0.82 | ROCK2 (0.61) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5401649 | 0.81 | PIK3CD (0.55) | ROCK2ROCK1CCR2CHRM4CHEK2 | |
| SCHEMBL5419161 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1CCR2CHRM4IKBKB | |
| SCHEMBL5416024 | 0.80 | ROCK2 (0.61) | ROCK2ROCK1CCR2CHRM4IKBKB | |
| SCHEMBL5407903 | 0.80 | PIK3CD (0.56) | ROCK2ROCK1CCR2CYP4A11CYP4F2 | |
| SCHEMBL5410231 | 0.80 | ROCK2 (0.56) | ROCK2ROCK1CCR2CHRM4HRH3 | |
| SCHEMBL5410943 | 0.80 | ROCK2 (0.65) | ROCK2ROCK1CCR2CHRM4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199147-B2 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20040138286-A1 | Rho kinase inhibitors | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138286-A1 | Rho kinase inhibitors | ROCK1, ROCK2, ARHGDIA | ROCK2 2/4885ROCK1 1/4885CCR2 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.